Literature DB >> 10176147

The effect of changes in treatment patterns on drug expenditure.

U G Gerdtham1, M Johannesson, B Gunnarsson, M Marcusson, F Henriksson.   

Abstract

This paper investigates the effects of changes in drug therapy on drug expenditure in Sweden between 1990 and 1995. Analyses have been carried out for both the aggregate drug expenditure and for drug expenditure according to the main groups of the Anatomical Therapeutic Chemical (ATC) classification system. Changes in expenditure can be divided into 3 components: the price of drugs, the quantity of drugs consumed and a residual. The size of the residual is a measure of the effect of changes in drug treatment patterns on drug expenditure. The aggregate real drug expenditure increased by 50% between 1990 and 1995. The relative retail price index of drugs decreased by 9% and the quantity index measured in terms of defined daily doses increased by 27%. The remaining residual increased by 30%. This implies that, if the residual had been unchanged during the study period, the aggregate expenditure would have increased by only 15%. The results also show that the size of the residual varies substantially across different ATC groups. The increase in the residual was largest for drugs that affect the nervous system (ATC group N); the residual increased by 86%. From the observed changes in residual values, it can be concluded that the underlying factor responsible for the increase in drug expenditure in Sweden is changes in drug therapy from less expensive to more expensive drugs.

Mesh:

Year:  1998        PMID: 10176147     DOI: 10.2165/00019053-199813010-00012

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  Cost-containment as part of pharmaceutical policy.

Authors:  Anna Birna Almarsdóttir; Janine M Traulsen
Journal:  Pharm World Sci       Date:  2005-06

Review 2.  Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece.

Authors:  E Karampli; K Souliotis; N Polyzos; J Kyriopoulos; E Chatzaki
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

3.  Why did drug spending increase during the 1990s? A decomposition based on Swedish data.

Authors:  Ulf-G Gerdtham; Douglas Lundin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  European healthcare policies for controlling drug expenditure.

Authors:  Silvia M Ess; Sebastian Schneeweiss; Thomas D Szucs
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Drivers of federal spending in pharmaceuticals of the Specialized Component: measurement and analysis.

Authors:  Fabiola Sulpino Vieira
Journal:  Rev Saude Publica       Date:  2021-12-08       Impact factor: 2.106

6.  Performance of a pharmaceutical services regionalization strategy policy in Minas Gerais, Brazil: Pre-post analysis from ERAF project.

Authors:  Tatiana Chama Borges Luz; Ana Karine Sarvel de Castro; Isabela Cristina Marques; Betania Barros Cota; Jèssica de Castro Alves; Michael Robert Law
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

7.  Factors influencing the variation in GMS prescribing expenditure in Ireland.

Authors:  A ConwayLenihan; S Ahern; S Moore; J Cronin; N Woods
Journal:  Health Econ Rev       Date:  2016-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.